FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093800129> ?p ?o ?g. }

• W3093800129 endingPage "43" @default.
• W3093800129 startingPage "39" @default.
• W3093800129 abstract "Objectives: The appearance of new drugs needs to represent 'a necessary option, however involves a challenge for healthcare decision makers. EMA is responsible for the scientific evaluation based on many aspects, but later there can be discrepancies between European drug approval and subsequent use. Our objective was to review EMA marketing authorizatioti of new active substance (NAS) and analyze the conditions and evidence of these. Also, we analyzed the opinion and reports of this NAS in The Spanish National Healthcare System. Method: We analyzed NAS who had received a positive opinion by EMA recommending the granting of a marketing authorization from 1st January 2014 to 31st December 2017, according to the dates of authorization details reflected on the EMA's website. We compiled: therapeutic area, indication, type of approval, route normally used, designation obtained and pivotal trials of drugs, according to their design features design, their clinical phase and the comparator, in order to evaluate the evidence provided. It was verified the existence of reports in the Spanish Dngs Agency and we analyzed its conclusions as well as the financing conditions. Results: A total of 136 NAS were approved, mainly in the ancology area. From them, 22 (16.2%) were conditional or exceptional approval. Otherwise, 22 (16.2%) of them were carried out by accelerated route. Of these drugs, 50 (36.8%) were authorized under orphan designation and 51 of the approved indications included at least a pivotal essay in phase I or II. Also, 54 trials included a placebo as a comparator and 27 are single-arm-essays. The Spanish-Drugs-Agency elaborated 132 reports. Most of them concluded that drugs were similar to than alternatives, considering their us; based on efficiency. Finally, 46 indications were not financed or financed under conditions. Conclusions: Our study shows that when a new drug is authorized, the evidence is low. This leads to uncertainties of efficacy and safety. The evaluation of the value is fundamental in the health system, and strategies are needed to improve the final outcomes with the limited available resources" @default.
• W3093800129 created "2020-10-29" @default.
• W3093800129 creator A5003445736 @default.
• W3093800129 creator A5029813180 @default.
• W3093800129 creator A5039307635 @default.
• W3093800129 creator A5046123092 @default.
• W3093800129 creator A5080569077 @default.
• W3093800129 creator A5090833570 @default.
• W3093800129 date "2020-01-01" @default.
• W3093800129 modified "2023-09-28" @default.
• W3093800129 title "Market access in the EU, do we have enough evidence?" @default.
• W3093800129 hasPublicationYear "2020" @default.
• W3093800129 type Work @default.
• W3093800129 sameAs 3093800129 @default.
• W3093800129 citedByCount "0" @default.
• W3093800129 crossrefType "journal-article" @default.
• W3093800129 hasAuthorship W3093800129A5003445736 @default.
• W3093800129 hasAuthorship W3093800129A5029813180 @default.
• W3093800129 hasAuthorship W3093800129A5039307635 @default.
• W3093800129 hasAuthorship W3093800129A5046123092 @default.
• W3093800129 hasAuthorship W3093800129A5080569077 @default.
• W3093800129 hasAuthorship W3093800129A5090833570 @default.
• W3093800129 hasConcept C10138342 @default.
• W3093800129 hasConcept C105639569 @default.
• W3093800129 hasConcept C108170787 @default.
• W3093800129 hasConcept C108759981 @default.
• W3093800129 hasConcept C111472728 @default.
• W3093800129 hasConcept C124056412 @default.
• W3093800129 hasConcept C138885662 @default.
• W3093800129 hasConcept C142724271 @default.
• W3093800129 hasConcept C144133560 @default.
• W3093800129 hasConcept C155202549 @default.
• W3093800129 hasConcept C160735492 @default.
• W3093800129 hasConcept C162118730 @default.
• W3093800129 hasConcept C162853370 @default.
• W3093800129 hasConcept C17744445 @default.
• W3093800129 hasConcept C182306322 @default.
• W3093800129 hasConcept C199539241 @default.
• W3093800129 hasConcept C2777589142 @default.
• W3093800129 hasConcept C2779598192 @default.
• W3093800129 hasConcept C2910001868 @default.
• W3093800129 hasConcept C2985089533 @default.
• W3093800129 hasConcept C3019806175 @default.
• W3093800129 hasConcept C38652104 @default.
• W3093800129 hasConcept C41008148 @default.
• W3093800129 hasConcept C512399662 @default.
• W3093800129 hasConcept C535046627 @default.
• W3093800129 hasConcept C60644358 @default.
• W3093800129 hasConcept C71924100 @default.
• W3093800129 hasConcept C75480439 @default.
• W3093800129 hasConcept C86803240 @default.
• W3093800129 hasConcept C98274493 @default.
• W3093800129 hasConceptScore W3093800129C10138342 @default.
• W3093800129 hasConceptScore W3093800129C105639569 @default.
• W3093800129 hasConceptScore W3093800129C108170787 @default.
• W3093800129 hasConceptScore W3093800129C108759981 @default.
• W3093800129 hasConceptScore W3093800129C111472728 @default.
• W3093800129 hasConceptScore W3093800129C124056412 @default.
• W3093800129 hasConceptScore W3093800129C138885662 @default.
• W3093800129 hasConceptScore W3093800129C142724271 @default.
• W3093800129 hasConceptScore W3093800129C144133560 @default.
• W3093800129 hasConceptScore W3093800129C155202549 @default.
• W3093800129 hasConceptScore W3093800129C160735492 @default.
• W3093800129 hasConceptScore W3093800129C162118730 @default.
• W3093800129 hasConceptScore W3093800129C162853370 @default.
• W3093800129 hasConceptScore W3093800129C17744445 @default.
• W3093800129 hasConceptScore W3093800129C182306322 @default.
• W3093800129 hasConceptScore W3093800129C199539241 @default.
• W3093800129 hasConceptScore W3093800129C2777589142 @default.
• W3093800129 hasConceptScore W3093800129C2779598192 @default.
• W3093800129 hasConceptScore W3093800129C2910001868 @default.
• W3093800129 hasConceptScore W3093800129C2985089533 @default.
• W3093800129 hasConceptScore W3093800129C3019806175 @default.
• W3093800129 hasConceptScore W3093800129C38652104 @default.
• W3093800129 hasConceptScore W3093800129C41008148 @default.
• W3093800129 hasConceptScore W3093800129C512399662 @default.
• W3093800129 hasConceptScore W3093800129C535046627 @default.
• W3093800129 hasConceptScore W3093800129C60644358 @default.
• W3093800129 hasConceptScore W3093800129C71924100 @default.
• W3093800129 hasConceptScore W3093800129C75480439 @default.
• W3093800129 hasConceptScore W3093800129C86803240 @default.
• W3093800129 hasConceptScore W3093800129C98274493 @default.
• W3093800129 hasIssue "1" @default.
• W3093800129 hasLocation W30938001291 @default.
• W3093800129 hasOpenAccess W3093800129 @default.
• W3093800129 hasPrimaryLocation W30938001291 @default.
• W3093800129 hasRelatedWork W1471212358 @default.
• W3093800129 hasRelatedWork W1575108358 @default.
• W3093800129 hasRelatedWork W1741190347 @default.
• W3093800129 hasRelatedWork W1846455356 @default.
• W3093800129 hasRelatedWork W1883414044 @default.
• W3093800129 hasRelatedWork W1937020882 @default.
• W3093800129 hasRelatedWork W1996267272 @default.
• W3093800129 hasRelatedWork W2005763656 @default.
• W3093800129 hasRelatedWork W201064510 @default.
• W3093800129 hasRelatedWork W2013270427 @default.
• W3093800129 hasRelatedWork W2055662005 @default.
• W3093800129 hasRelatedWork W2153884870 @default.

• next